Filters

by AllCells

Showing 25 of 16 items meeting your criteria.
Items per page
 TypeCategorySupplier 
 
AllCells GMP-compliant cryopreserved leukopak products offer the quality and consistency of fresh leukapheresis material with the benefit of extended shelf life and stability for reliable and flexible access to starting material for downstream cell and gene therapy manufacturing, no matter your timeline.
Documents
Human Blood Products
AllCells
Peripheral blood is collected from IRB-consented donors using the continuous flow Spectra Optia® Apheresis System directly into ACD-A anticoagulant at AllCells FDA-registered, IRB-approved collection facilities. Fresh leukapheresis material is immediately processed in adjacent processing facilities. The leukopaks are cryopreserved in CryoStor® CS10 using conduction-cooled controlled rate freezers. All cryopreservation steps occur within class ISO 7 cleanroom with grade A and B zones according to Master Batch Record. GMP-Compliant Cryopreserved Leukopak are quality controlled for pre-cryopreservation cell count and viability using a validated AO/PI protocol and meet the strict quality standards as defined by the FDA (21 CFR 1271) and AABB.
Documents
Human Blood Products
AllCells
T cells are the main effector cells of the adaptive immune system. They can be distinguished from other white blood cells by the presence of a T-cell receptor (TCR) on their cell surface. Differentiated from bone marrow-derived hematopoietic stem cells, T cells migrate to the thymus gland where they mature into CD4 and CD8 T cells. Further differentiation occurs in the periphery of CD4 and CD8 T cells into several distinct subtypes, each with distinct roles during the formation of an immune response. These lymphocytes are of great interest for a wide range of research and translational medicine applications.
Documents
Human Blood Products
AllCells
Cell and gene therapies are at the forefront of medical innovation, transforming how we treat and potentially cure certain diseases that have previously lacked an effective treatment. Robust clinical pipelines and a growing list of FDA-approved therapies brings hope to many patients, placing tremendous pressure on biopharma companies to accelerate development to meet the growing demand. In contrast to traditional biologics (i.e., monoclonal antibodies), the cells themselves are the therapeutic agent. Therefore, clinical success of cell and gene therapies hinges on access to a consistent and high-quality supply of cellular starting material, which are inherently vulnerable to supply chain complications and setbacks. This is further compounded when donors with unique (and potentially rare) attributes are needed. Partnering with an established and reputable supplier like AllCells can bridge the gap and enable the identification of (and collection from) the right donors that can allow companies to move swiftly from therapeutic discovery to commercialization.
Documents
Human Blood Products
AllCells
Natural killer (NK) cells are members of the innate immune system representing 5-20% of the circulating lymphocytes. Classified as group I Innate Lymphocytes (ILCs), they arise from the same lymphoid progenitor cells as T and B cells and play a critical role in immune surveillance and can mount rapid immune responses to a wide variety of pathological challenges.
Documents
Human Blood Products
AllCells
CD34+ stem cells have the capacity for self-renewal, making them a valuable source of hematopoietic stem and progenitor cells for cell therapies. In fact, allogeneic hematopoietic stem cell (HSC) transplantation has been used routinely as a curative treatment for indications in oncology and regenerative medicine. However, challenges with HLA-matching and potential risk of graft vs. host disease (GvHD) has led to a surge in the development of autologous and allogeneic genetically engineered HSC therapies as alternative treatments. As these programs mature, there is a need for GMP-compliant Mobilized Leukopaks — enriched in high-quality CD34+ cells—to support process validation and qualification. AllCells GMP-compliant Mobilized Leukopaks overcome donor and process variability to mitigate risk in downstream applications to accelerate time-to-market.
Documents
Human Blood Products
AllCells
The isolation of specific cell populations from blood products via immunomagnetic cell separation remains an integral operation in any research organization to enrich target cells for immunology and other fields in life sciences. Outsourcing this time-consuming process to an external supplier can streamline your labs workflow and liberate in-house personnel to focus on other priorities. Bulk isolation by a qualified vendor provides all the quality assurances of a commercial product without incurring any capital or operational costs in house. Get high-yield cell products from a single-donor source. Standard and sequential isolations are available.
Documents
Human Blood Products
AllCells
It is advantageous to identify suitable clinical grade, GMP-compliant raw materials and reliable supply partners early in preclinical development to support rapid and seamless clinical translation of a cell and gene therapy (CGT) candidate. There are very few GMP suppliers who can fulfill the regulatory requirements for donor-sourced materials and identifying one can be a lengthy process. Securing these partnerships early and building in time for vendor evaluation, project discussions and design, documentation, and donor screening can help prevent delays downstream.
Documents
Human Blood Products
AllCells
Technical bulletin for HUMAN BONE MARROW ASPIRATE.
Documents
Human Blood Products
AllCells
By leveraging their recruiting expertise, coupled with novel marketing tactics, AllCells industry-leading donor management program recruits and collects from donors with sickle cell trait (SCT), providing a rare resource to bridge the gap for researchers working to treat SCD.
Documents
Human Blood Products
AllCells
Leukopaks are an enriched leukapheresis product collected from the peripheral blood from a single donor consisting of a large number of mononuclear cells (T cells, B cells, NK cells, and monocytes). Leukapheresis collections result in higher purity and significantly higher MNC content compared to from buffy coat collection. Obtaining higher purity and higher quantities of mononuclear cells (MNCs) is important for research and clinical uses such as cell-based assays (proliferation, T cell activation, etc), cell therapy process development, bio-marker discovery and more.
Documents
Human Blood Products
AllCells
Leukopaks, collected from peripheral blood from a single donor, are an enriched source of mononuclear cells (T cells, B cells, NK cells, and monocytes). Leukapheresis collections provide higher purity and quantity of mononuclear cells (MNCs) than buffy coat collection, which is desirable for research and clinical uses such as cell-based assays (proliferation, T cell activation, etc), cell therapy process development, biomarker discovery and more.
Documents
Human Blood Products
AllCells
Monocytes are large agranular leukocytes comprising ~ 5% - 10% of the circulating white blood cells.
Documents
Human Blood Products
AllCells
Since its inception in 1998, AllCells has been providing primary cell products to support the cell and gene therapy industry. In 2022, AllCells joined Discovery Life Sciences to expand its capabilities and serve the entire cell and gene therapy continuum — from basic discovery through commercialisation. With more than 30 years of collective industry experience, AllCells and Discovery will focus on providing revolutionary products and services with greater speed and reliability.
Documents
Human Blood Products
AllCells
Sourcing high-quality cellular material is one of the biggest industry challenges for the development of cell and gene therapies. AllCells, a Discovery Life Sciences company, is the industry leader in providing GMP-compliant and RUO starting materials to support the full continuum of cell and gene therapy production – from basic discovery through commercialisation. Operating the largest and most diverse repository of healthy, recallable donors, AllCells is well-suited to fulfil a variety of donor attributes.
Documents
Human Blood Products
AllCells
Mobilized Leukopaks are apheresis products collected from healthy donors treated with different FDA-approved drugs to stimulate mobilization of CD34+ hematopoietic stem and progenitor cells (HSPCs) from the bone marrow to the peripheral blood. This procedure results in large-scale yields of single-donor CD34+ HSPCs, allowing for scalability and reproducibility of experiments by limiting the impact of donor-to-donor variability.
Documents
Human Blood Products
AllCells